Progress with infliximab biosimilars for inflammatory bowel disease

Zsuzsanna Kurti, Lorant Gonczi, P. Lakatos

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Biological therapies have revolutionized the treatment of inflammatory bowel diseases (IBD) in the last two decades. Though biological drugs are effective, their use is associated with high costs and access to biological agents varies among countries. As the patent for the reference products expired, the advent of biosimilar monoclonal antibodies has been expected. Biosimilars represent less expensive alternatives compared to the reference product. Areas covered: In this review, authors will review the literature on the clinical efficacy, safety and immunogenicity of current and future biosimilar infliximabs. Short- and medium-term data from real-life cohorts and from randomized-clinical trials in IBD demonstrated similar outcomes in terms of efficacy, safety and immunogenicity as the reference product for CT-P13. Switch data from the reference to the biosimilar product are also accumulating (including the NOR-SWITCH and the CT-P13 3.4 study). Expert opinion: The use of biosimilar infliximab in IBD is increasing worldwide. Its use may be associated with budget savings leading to better access to biological therapies and consequently improved health outcomes. Switching from the originator to a biosimilar in patients with IBD is acceptable, although scientific and clinical evidence is lacking regarding reverse switching, multiple switching, and cross-switching among biosimilars in IBD patients.

Original languageEnglish
Pages (from-to)633-640
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume18
Issue number6
DOIs
Publication statusPublished - Jun 3 2018

Fingerprint

Biosimilar Pharmaceuticals
Inflammatory Bowel Diseases
Biological Therapy
Safety
Expert Testimony
Biological Factors
Budgets
Infliximab
Randomized Controlled Trials
Monoclonal Antibodies
Switches

Keywords

  • anti-TNF
  • biological therapy
  • biosimilar
  • Crohn’s disease
  • CT-P13
  • inflammatory bowel disease
  • Infliximab
  • ulcerative colitis

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Progress with infliximab biosimilars for inflammatory bowel disease. / Kurti, Zsuzsanna; Gonczi, Lorant; Lakatos, P.

In: Expert Opinion on Biological Therapy, Vol. 18, No. 6, 03.06.2018, p. 633-640.

Research output: Contribution to journalReview article

Kurti, Zsuzsanna ; Gonczi, Lorant ; Lakatos, P. / Progress with infliximab biosimilars for inflammatory bowel disease. In: Expert Opinion on Biological Therapy. 2018 ; Vol. 18, No. 6. pp. 633-640.
@article{180d02daf6564f76b87ed6072a84c16b,
title = "Progress with infliximab biosimilars for inflammatory bowel disease",
abstract = "Introduction: Biological therapies have revolutionized the treatment of inflammatory bowel diseases (IBD) in the last two decades. Though biological drugs are effective, their use is associated with high costs and access to biological agents varies among countries. As the patent for the reference products expired, the advent of biosimilar monoclonal antibodies has been expected. Biosimilars represent less expensive alternatives compared to the reference product. Areas covered: In this review, authors will review the literature on the clinical efficacy, safety and immunogenicity of current and future biosimilar infliximabs. Short- and medium-term data from real-life cohorts and from randomized-clinical trials in IBD demonstrated similar outcomes in terms of efficacy, safety and immunogenicity as the reference product for CT-P13. Switch data from the reference to the biosimilar product are also accumulating (including the NOR-SWITCH and the CT-P13 3.4 study). Expert opinion: The use of biosimilar infliximab in IBD is increasing worldwide. Its use may be associated with budget savings leading to better access to biological therapies and consequently improved health outcomes. Switching from the originator to a biosimilar in patients with IBD is acceptable, although scientific and clinical evidence is lacking regarding reverse switching, multiple switching, and cross-switching among biosimilars in IBD patients.",
keywords = "anti-TNF, biological therapy, biosimilar, Crohn’s disease, CT-P13, inflammatory bowel disease, Infliximab, ulcerative colitis",
author = "Zsuzsanna Kurti and Lorant Gonczi and P. Lakatos",
year = "2018",
month = "6",
day = "3",
doi = "10.1080/14712598.2018.1469620",
language = "English",
volume = "18",
pages = "633--640",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Progress with infliximab biosimilars for inflammatory bowel disease

AU - Kurti, Zsuzsanna

AU - Gonczi, Lorant

AU - Lakatos, P.

PY - 2018/6/3

Y1 - 2018/6/3

N2 - Introduction: Biological therapies have revolutionized the treatment of inflammatory bowel diseases (IBD) in the last two decades. Though biological drugs are effective, their use is associated with high costs and access to biological agents varies among countries. As the patent for the reference products expired, the advent of biosimilar monoclonal antibodies has been expected. Biosimilars represent less expensive alternatives compared to the reference product. Areas covered: In this review, authors will review the literature on the clinical efficacy, safety and immunogenicity of current and future biosimilar infliximabs. Short- and medium-term data from real-life cohorts and from randomized-clinical trials in IBD demonstrated similar outcomes in terms of efficacy, safety and immunogenicity as the reference product for CT-P13. Switch data from the reference to the biosimilar product are also accumulating (including the NOR-SWITCH and the CT-P13 3.4 study). Expert opinion: The use of biosimilar infliximab in IBD is increasing worldwide. Its use may be associated with budget savings leading to better access to biological therapies and consequently improved health outcomes. Switching from the originator to a biosimilar in patients with IBD is acceptable, although scientific and clinical evidence is lacking regarding reverse switching, multiple switching, and cross-switching among biosimilars in IBD patients.

AB - Introduction: Biological therapies have revolutionized the treatment of inflammatory bowel diseases (IBD) in the last two decades. Though biological drugs are effective, their use is associated with high costs and access to biological agents varies among countries. As the patent for the reference products expired, the advent of biosimilar monoclonal antibodies has been expected. Biosimilars represent less expensive alternatives compared to the reference product. Areas covered: In this review, authors will review the literature on the clinical efficacy, safety and immunogenicity of current and future biosimilar infliximabs. Short- and medium-term data from real-life cohorts and from randomized-clinical trials in IBD demonstrated similar outcomes in terms of efficacy, safety and immunogenicity as the reference product for CT-P13. Switch data from the reference to the biosimilar product are also accumulating (including the NOR-SWITCH and the CT-P13 3.4 study). Expert opinion: The use of biosimilar infliximab in IBD is increasing worldwide. Its use may be associated with budget savings leading to better access to biological therapies and consequently improved health outcomes. Switching from the originator to a biosimilar in patients with IBD is acceptable, although scientific and clinical evidence is lacking regarding reverse switching, multiple switching, and cross-switching among biosimilars in IBD patients.

KW - anti-TNF

KW - biological therapy

KW - biosimilar

KW - Crohn’s disease

KW - CT-P13

KW - inflammatory bowel disease

KW - Infliximab

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85048303532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048303532&partnerID=8YFLogxK

U2 - 10.1080/14712598.2018.1469620

DO - 10.1080/14712598.2018.1469620

M3 - Review article

VL - 18

SP - 633

EP - 640

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 6

ER -